Literature DB >> 23769412

Translating next generation sequencing to practice: opportunities and necessary steps.

Sitharthan Kamalakaran1, Vinay Varadan, Angel Janevski, Nilanjana Banerjee, David Tuck, W Richard McCombie, Nevenka Dimitrova, Lyndsay N Harris.   

Abstract

Next-generation sequencing (NGS) approaches for measuring RNA and DNA benefit from greatly increased sensitivity, dynamic range and detection of novel transcripts. These technologies are rapidly becoming the standard for molecular assays and represent huge potential value to the practice of oncology. However, many challenges exist in the transition of these technologies from research application to clinical practice. This review discusses the value of NGS in detecting mutations, copy number changes and RNA quantification and their applications in oncology, the challenges for adoption and the relevant steps that are needed for translating this potential to routine practice.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Keywords:  Genomics; Next generation sequencing; Oncology; Personalized medicine

Mesh:

Year:  2013        PMID: 23769412      PMCID: PMC5528427          DOI: 10.1016/j.molonc.2013.04.008

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  79 in total

1.  Challenges in the clinical application of whole-genome sequencing.

Authors:  Kelly E Ormond; Matthew T Wheeler; Louanne Hudgins; Teri E Klein; Atul J Butte; Russ B Altman; Euan A Ashley; Henry T Greely
Journal:  Lancet       Date:  2010-04-29       Impact factor: 79.321

Review 2.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

Review 3.  Next-generation sequencing data interpretation: enhancing reproducibility and accessibility.

Authors:  Anton Nekrutenko; James Taylor
Journal:  Nat Rev Genet       Date:  2012-09       Impact factor: 53.242

4.  The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.

Authors:  A Kohlmann; H-U Klein; S Weissmann; S Bresolin; T Chaplin; H Cuppens; E Haschke-Becher; B Garicochea; V Grossmann; B Hanczaruk; K Hebestreit; C Gabriel; I Iacobucci; J H Jansen; G te Kronnie; L van de Locht; G Martinelli; K McGowan; M R Schweiger; B Timmermann; P Vandenberghe; B D Young; M Dugas; T Haferlach
Journal:  Leukemia       Date:  2011-06-17       Impact factor: 11.528

5.  NRAS mutations are rare in colorectal cancer.

Authors:  Natsumi Irahara; Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Liying Yan; Dora Dias-Santagata; Anthony John Iafrate; Charles S Fuchs; Kevin M Haigis; Shuji Ogino
Journal:  Diagn Mol Pathol       Date:  2010-09

Review 6.  From clinical practice guidelines to computer-interpretable guidelines. A literature overview.

Authors:  A Latoszek-Berendsen; H Tange; H J van den Herik; A Hasman
Journal:  Methods Inf Med       Date:  2010-11-18       Impact factor: 2.176

7.  Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.

Authors:  K A Voutilainen; M A Anttila; S M Sillanpää; K M Ropponen; S V Saarikoski; M T Juhola; V-M Kosma
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

Review 8.  The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.

Authors:  Federico A Monzon; Shuji Ogino; M Elizabeth H Hammond; Kevin C Halling; Kenneth J Bloom; Marina N Nikiforova
Journal:  Arch Pathol Lab Med       Date:  2009-10       Impact factor: 5.534

9.  Assuring the quality of next-generation sequencing in clinical laboratory practice.

Authors:  Amy S Gargis; Lisa Kalman; Meredith W Berry; David P Bick; David P Dimmock; Tina Hambuch; Fei Lu; Elaine Lyon; Karl V Voelkerding; Barbara A Zehnbauer; Richa Agarwala; Sarah F Bennett; Bin Chen; Ephrem L H Chin; John G Compton; Soma Das; Daniel H Farkas; Matthew J Ferber; Birgit H Funke; Manohar R Furtado; Lilia M Ganova-Raeva; Ute Geigenmüller; Sandra J Gunselman; Madhuri R Hegde; Philip L F Johnson; Andrew Kasarskis; Shashikant Kulkarni; Thomas Lenk; C S Jonathan Liu; Megan Manion; Teri A Manolio; Elaine R Mardis; Jason D Merker; Mangalathu S Rajeevan; Martin G Reese; Heidi L Rehm; Birgitte B Simen; Joanne M Yeakley; Justin M Zook; Ira M Lubin
Journal:  Nat Biotechnol       Date:  2012-11       Impact factor: 54.908

10.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Authors:  Daniel P Silver; Andrea L Richardson; Aron C Eklund; Zhigang C Wang; Zoltan Szallasi; Qiyuan Li; Nicolai Juul; Chee-Onn Leong; Diana Calogrias; Ayodele Buraimoh; Aquila Fatima; Rebecca S Gelman; Paula D Ryan; Nadine M Tung; Arcangela De Nicolo; Shridar Ganesan; Alexander Miron; Christian Colin; Dennis C Sgroi; Leif W Ellisen; Eric P Winer; Judy E Garber
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

View more
  12 in total

Review 1.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

2.  A new model for reimbursing genome-based cancer care.

Authors:  Scott D Ramsey; Sean D Sullivan
Journal:  Oncologist       Date:  2013-12-05

3.  Describing sequencing results of structural chromosome rearrangements with a suggested next-generation cytogenetic nomenclature.

Authors:  Zehra Ordulu; Kristen E Wong; Benjamin B Currall; Andrew R Ivanov; Shahrin Pereira; Sara Althari; James F Gusella; Michael E Talkowski; Cynthia C Morton
Journal:  Am J Hum Genet       Date:  2014-04-17       Impact factor: 11.025

4.  Clinical integration of next generation sequencing: coverage and reimbursement challenges.

Authors:  Patricia A Deverka; Jennifer C Dreyfus
Journal:  J Law Med Ethics       Date:  2014       Impact factor: 1.718

Review 5.  Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review.

Authors:  Henry T Lynch; Kristen Drescher; Joseph Knezetic; Stephen Lanspa
Journal:  Curr Treat Options Oncol       Date:  2014-09

6.  CloneCNA: detecting subclonal somatic copy number alterations in heterogeneous tumor samples from whole-exome sequencing data.

Authors:  Zhenhua Yu; Ao Li; Minghui Wang
Journal:  BMC Bioinformatics       Date:  2016-08-19       Impact factor: 3.169

Review 7.  Next-generation sequencing: recent applications to the analysis of colorectal cancer.

Authors:  Filippo Del Vecchio; Valentina Mastroiaco; Antinisca Di Marco; Chiara Compagnoni; Daria Capece; Francesca Zazzeroni; Carlo Capalbo; Edoardo Alesse; Alessandra Tessitore
Journal:  J Transl Med       Date:  2017-12-08       Impact factor: 5.531

8.  Towards precision medicine: discovering novel gynecological cancer biomarkers and pathways using linked data.

Authors:  Alokkumar Jha; Yasar Khan; Muntazir Mehdi; Md Rezaul Karim; Qaiser Mehmood; Achille Zappa; Dietrich Rebholz-Schuhmann; Ratnesh Sahay
Journal:  J Biomed Semantics       Date:  2017-09-19

9.  ENVE: a novel computational framework characterizes copy-number mutational landscapes in colorectal cancers from African American patients.

Authors:  Vinay Varadan; Salendra Singh; Arman Nosrati; Lakshmeswari Ravi; James Lutterbaugh; Jill S Barnholtz-Sloan; Sanford D Markowitz; Joseph E Willis; Kishore Guda
Journal:  Genome Med       Date:  2015-07-20       Impact factor: 11.117

Review 10.  Unsolved challenges of clinical whole-exome sequencing: a systematic literature review of end-users' views.

Authors:  Gabrielle Bertier; Martin Hétu; Yann Joly
Journal:  BMC Med Genomics       Date:  2016-08-11       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.